摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-环丙基-5-溴吡啶甲酰胺 | 638219-77-9

中文名称
N-环丙基-5-溴吡啶甲酰胺
中文别名
N-环丙基5-溴吡啶甲酰胺
英文名称
5-bromo-2-(N-cyclopropylaminocarbonyl)pyridine
英文别名
5-bromo-N-cyclopropylpicolinamide;5-bromo-pyridine-2-carboxylic acid cyclopropylamide;5-Bromo-N-cyclopropylpyridine-2-carboxamide
N-环丙基-5-溴吡啶甲酰胺化学式
CAS
638219-77-9
化学式
C9H9BrN2O
mdl
——
分子量
241.087
InChiKey
MBQYBUFHINSBNB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    389.5±27.0 °C(Predicted)
  • 密度:
    1.62±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    42
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S26
  • 危险类别码:
    R22,R36
  • 海关编码:
    2933399090

SDS

SDS:7d26841fd28952052f6bd3220ef63242
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: N-Cyclopropyl 5-bromopicolinamide
Synonyms: 5-Bromo-N-cyclopropylpicolinamide; N-cyclopropyl 5-bromopyridine-2-carboxamide

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

Section 3. Composition/information on ingredients.
Ingredient name: N-Cyclopropyl 5-bromopicolinamide
CAS number: 638219-77-9

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H9BrN2O
Molecular weight: 241.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    参考文献:
    名称:
    设计,合成和生物评价的8-biarylquinolines:一类新型的PDE4抑制剂。
    摘要:
    本文描述了充当4型磷酸二酯酶(PDE4)抑制剂的一系列新的8-联芳基喹啉系列的结构-活性关系。该系列的典型化合物是四种不同PDE4(IC(50)<10 nM)同功酶(AD)的有效和非选择性抑制剂。在人类全血体外测定中,它们抑制(IC(50)<0.5 microM)LPS诱导的细胞因子TNF-α释放。在清醒的豚鼠中,在卵清蛋白诱导的支气管收缩模型中评估了优化的抑制剂的体内功效。通过在松鼠猴中进行药代动力学研究,评估了它们产生催吐反应的倾向。这项工作已导致鉴定出几种具有优异的体外和体内特性的化合物,其中包括治疗呕吐的良好治疗窗口。
    DOI:
    10.1016/j.bmcl.2008.01.004
  • 作为产物:
    描述:
    参考文献:
    名称:
    [EN] 8-(BIARYL) QUINOLINE PDE4 INHIBITORS
    [FR] INHIBITEURS DE PDE4 8-(BIARYLE)QUINOLINES
    摘要:
    8-(联苯基)喹啉类化合物,其中在8位的联苯基与喹啉基团呈间位关系,是磷酸二酯酶4抑制剂,在治疗哮喘、慢性支气管炎、慢性阻塞性肺疾病、嗜酸性肉芽肿、牛皮癣和其他良性或恶性增生性皮肤疾病、内毒素休克、马蹄炎、马胃肠炎、脓毒性休克、溃疡性结肠炎、克罗恩病、心肌和脑再灌注损伤、炎症性关节炎、慢性肾小球肾炎、特应性皮炎、荨麻疹、成人呼吸窘迫综合征、动物慢性阻塞性肺疾病、尿崩症、过敏性鼻炎、过敏性结膜炎、春季结膜炎、动脉再狭窄、动脉粥样硬化、动脉粥样硬化、神经源性炎症、疼痛、咳嗽、类风湿性关节炎、强直性脊柱炎、移植排斥反应、移植物抗宿主病、胃酸过多分泌、细菌、真菌诱导的败血症、病毒诱导的败血症、真菌诱导的脓毒性休克、病毒诱导的脓毒性休克、炎症介导的慢性组织退行性变、细胞因子介导的慢性组织退行性变、骨关节炎、癌症、虚弱、肌肉消耗、抑郁症、记忆障碍、肿瘤生长或癌细胞侵袭正常组织。另一方面,本发明涉及一种增强健康受试者认知能力的方法,包括给予安全的增强认知量的磷酸二酯酶4抑制剂。具体而言,本发明涉及一种增强健康受试者记忆、学习、保留、回忆、意识和判断能力的方法,包括给予安全且增强认知量的磷酸二酯酶4抑制剂。
    公开号:
    WO2004000814A1
点击查看最新优质反应信息

文献信息

  • N
    申请人:浙江大学
    公开号:CN111732548B
    公开(公告)日:2022-06-17
    本发明提供N2‑氨甲酰芳环‑2‑氨基嘧啶类衍生物及其医药用途。本发明提供的N2‑氨甲酰芳环‑2‑氨基嘧啶衍生物包括其光学异构体及药学上可接受的盐。经药效研究表明,所述化合物具有FLT3抑制活性,对多种白血病细胞株有增值抑制活性,对乳腺癌细胞有中等抑制作用,且对AML多种突变如近膜结构域的内部串联重复突变和激酶结构域中活化环的D835点突变有效,对c‑KIT几乎无抑制作用,可以克服临床上点突变带来的耐药,可以减小骨髓抑制毒副作用,可在制备抗肿瘤药物中的应用。N2‑氨甲酰芳环‑2‑氨基嘧啶类衍生物的通式Ia和Ib的结构如下:
  • Amido compounds and their use as pharmaceuticals
    申请人:Yao Wenqing
    公开号:US20050282858A1
    公开(公告)日:2005-12-22
    The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
    本发明涉及11-β羟基类固醇脱氢酶1型的抑制剂,矿物质皮质激素受体(MR)的拮抗剂以及其制药组合物。本发明的化合物可用于治疗与11-β羟基类固醇脱氢酶1型的表达或活性有关的各种疾病和/或与醛固酮过多有关的疾病。
  • 8-(Biaryl)quinoline pde4 inhibitors
    申请人:Dube Daniel
    公开号:US20050234238A1
    公开(公告)日:2005-10-20
    8-(biaryl) quinolines wherein the bi-aryl group at the 8-position is in a meta relationship to the quinoline group, are PDE4 inhibitors useful in the treatment of asthma, chronic bronchitis, chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock, laminitis in horses, colic in horses, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, ortherosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, ankylosing spondylitis, transplant rejection, graft versus host disease, hypersecretion of gastric acid, bacterial, fungal induced sepsis, viral induced sepsis, fungal induced septic shock, viral induced septic shock, inflammation-mediated chronic tissue degeneration, cytokine-mediated chronic tissue degeneration, osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, tumour growth, or cancerous invasion of normal tissues. In another aspect, the present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a safe and cognition enhancing amount of a phosphodiesterase-4 inhibitor.
    8-(联苯基)喹啉中,8位位置的联苯基与喹啉基团呈间位关系,是PDE4抑制剂,可用于治疗哮喘、慢性支气管炎、慢性阻塞性肺疾病、嗜酸性粒细胞肉芽肿、银屑病和其他良性或恶性增生性皮肤疾病、内毒素休克、马蹄疾病、马腹绞痛、败血症休克、溃疡性结肠炎、克罗恩病、心肌和脑再灌注损伤、炎性关节炎、慢性肾小球肾炎、特应性皮炎、荨麻疹、成人呼吸窘迫综合症、动物慢性阻塞性肺疾病、尿崩症、过敏性鼻炎、过敏性结膜炎、春季结膜炎、动脉再狭窄、动脉硬化、神经源性炎症、疼痛、咳嗽、类风湿性关节炎、强直性脊柱炎、移植排斥、移植物抗宿主病、胃酸分泌过多、细菌、真菌引起的败血症、病毒引起的败血症、真菌引起的败血性休克、病毒引起的败血性休克、炎症介导的慢性组织退化、细胞因子介导的慢性组织退化、骨关节炎、癌症、消瘦、肌肉消耗、抑郁症、记忆障碍、肿瘤生长或癌细胞侵袭正常组织。另一方面,本发明还涉及一种增强健康受试者认知能力的方法,包括给予安全的认知增强剂量的磷酸二酯酶-4抑制剂。特别地,本发明涉及一种增强健康受试者记忆、学习、保留、回忆、意识和判断能力的方法,包括给予安全的认知增强剂量的磷酸二酯酶-4抑制剂。
  • 8-(biaryl)quinoline PDE4 inhibitors
    申请人:Merck Frosst Canada, Ltd.
    公开号:US07153968B2
    公开(公告)日:2006-12-26
    8-(biaryl) quinolines wherein the bi-aryl group at the 8-position is in a meta relationship to the quinoline group, are PDE4 inhibitors useful in the treatment of asthma, chronic bronchitis, chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock, laminitis in horses, colic in horses, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, ortherosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, ankylosing spondylitis, transplant rejection, graft versus host disease, hypersecretion of gastric acid, bacterial, fungal induced sepsis, viral induced sepsis, fungal induced septic shock, viral induced septic shock, inflammation-mediated chronic tissue degeneration, cytokine-mediated chronic tissue degeneration, osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, tumour growth, or cancerous invasion of normal tissues. In another aspect, the present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a safe and cognition enhancing amount of a phosphodiesterase-4 inhibitor.
    8-(联苯基)喹啉类化合物,其中8位的联苯基与喹啉基团呈间位关系,是PDE4抑制剂,可用于治疗哮喘、慢性支气管炎、慢性阻塞性肺疾病、嗜酸性粒细胞肉芽肿、银屑病和其他良性或恶性增生性皮肤疾病、内毒素休克、马蹄骨炎、马腹绞痛、败血症休克、溃疡性结肠炎、克罗恩病、心肌和脑再灌注损伤、炎性关节炎、慢性肾小球肾炎、特应性皮炎、荨麻疹、成人呼吸窘迫综合症、动物慢性阻塞性肺疾病、尿崩症、过敏性鼻炎、过敏性结膜炎、春季性结膜炎、动脉再狭窄、动脉粥样硬化、神经源性炎症、疼痛、咳嗽、类风湿性关节炎、强直性脊柱炎、移植排斥反应、移植物抗宿主病、胃酸过多、细菌、真菌感染引起的败血症、病毒感染引起的败血症、真菌感染引起的败血性休克、病毒感染引起的败血性休克、炎症介导的慢性组织退化、细胞因子介导的慢性组织退化、骨关节炎、癌症、消瘦、肌肉萎缩、抑郁症、记忆障碍、肿瘤生长或癌细胞侵袭正常组织。在另一个方面,本发明涉及一种增强健康受试者认知能力的方法,包括给予安全的增强认知剂量的磷酸二酯酶-4抑制剂。特别是,本发明涉及一种增强健康受试者记忆、学习、保留、回忆、意识和判断的方法,包括给予安全的增强认知剂量的磷酸二酯酶-4抑制剂。
  • Amido Compounds And Their Use As Pharmaceuticals
    申请人:Yao Wenqing
    公开号:US20080255154A1
    公开(公告)日:2008-10-16
    The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
    本发明涉及11-β羟基类固醇脱氢酶1型的抑制剂、矿物质皮质激素受体(MR)的拮抗剂及其制药组合物。本发明的化合物可用于治疗与11-β羟基类固醇脱氢酶1型的表达或活性有关的各种疾病和/或与醛固酮过多有关的疾病。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-